Key result
In a registry of 787 patients hospitalized with acute or decompensated heart failure in Iran, the 1-year mortality rate was 30.9% and the in-hospital mortality was 6.2%.
Observational (n=787)
Yes
The PROVE/HF registry pilot phase demonstrated high annual rates of re-admission and mortality among hospitalized heart failure patients in Iran, highlighting suboptimal guideline-directed medical therapy use.
May prompt review of HF management in Iran; leaves open whether GDMT optimization improves survival.
BACKGROUND: The Persian Registry of Cardiovascular disease/Heart Failure (PROVE/HF) aimed to studied the demographic, clinical, and diagnostic characteristics and treatment of patients hospitalized for heart failure (HF) and to follow them for short- and long-term outcomes. Its pilot phase started in 2015 in Isfahan aiming to evaluate its feasibility to be scaled up at the national level in later stages. This article describes the method and preliminary results of the first year registry. MATERIALS AND METHODS: Information of hospitalized patients with preserved and low ejection fraction, were gathered. Patients were followed for 1, 6, and 12 months. During follow-up, information of the patients' current status, medications used during hospitalization, and in case of death, the cause and place were assessed. RESULT: PROVE/ HF enrolled 787 patients in the first year. The mean age of patients was 70.74 ±12.01 years, and 60.7% of them were men. The most frequent risk factors for the development of HF in the recruited patients was ischemic heart disease (77.9%), and hypertension (63.7%), respectively. The re-admission rate for patients with HF was at least once in 16% and continued until the fifth to ninth re-admission over a one-year period. Among 787 registered patients, 30.9% died in the first year of follow-up, and the in-hospital mortality was 6.2%. The mean hospitalization period was 4.88 days, and 64.2% were hospitalized for >3 days. CONCLUSION: The annual rate of re-admission and mortality was high, and the use of medication was less than the recommended one inaccordance with the guidelines for the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Givi et al. (2018) conducted an observational in Heart Failure (n=787). Acute or decompensated heart failure was evaluated on 1-year mortality. In a registry of 787 patients hospitalized with acute or decompensated heart failure in Iran, the 1-year mortality rate was 30.9% and the in-hospital mortality was 6.2%.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: